Health Canada approves ruxolitinib for PV patients
Published February 19, 2016.
Health Canada has approved ruxolitinib (Jakavi®) for the control of hematocrit in adult patients with polycythemia vera (PV) who are resistant to or intolerant of a cytoreductive agent.